Special Issue "Beyond Immunotherapy in the Management of Genito-Urinary Malignancies"
Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 6759
Interests: genito-urinary malignancies; early phase drug trials; immunotherapy; predictive biomarkers and microbiome studies
Immunotherapy with immune checkpoint inhibitors (ICIs) has changed oncology practice in the last decade. The members of this class of agents include: ipilimumab, a cytotoxic T lymphocyte-associated protein 4 (CTLA-4) inhibitor; nivolumab and pembrolizumab, antiprogrammed cell death 1 (PD-1) agents; atezolizumab, durvalumab, and avelumab, which are antiprogrammed cell death-ligand 1 (PD-L1) agents. ICIs have become the standard treatment in genito-urinary malignancies, including first-line and second-line treatments for renal cell carcinoma and urothelial carcinoma.
Despite the clinical efficacy of the checkpoint blockade, most cancer patients still do not derive durable benefits from these therapies. Moreover, ICIs can induce various immune-related adverse events (irAEs), limiting their use in many patients. ICIs may affect peripheral tolerance to autoantigens, resulting in autoantibody formation, which could be associated with irAEs in various organs. Therefore, there is a need for additional therapeutic approaches. Several clinical trials are ongoing with different therapies, including chemotherapy, antibody–drug conjugates, agents targeting additional immune checkpoint pathways, vaccines, cytokines, adoptive cell therapies, as well as targeted and antiangiogenic agents. The biology of each disease and optimal sequencing of active therapies are key points that are being evaluated in prospective clinical trials. Current challenges include molecular heterogeneity, clonal evolution, genomic instability, identifying and utilizing biomarkers that predict survival and/or treatment response, and identifying optimal tools to help guide precision medicine.
This Special Issue aims to review biological underpinnings, clinical strategies and potential future directions of promising therapeutic targets in uro-oncology and how this knowledge may inform the future landscape of these diseases.
Dr. Ricardo Fernandes
Dr. Aly-Khan Lalani
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- immune checkpoint inhibitors
- genito-urinary malignancies
- precision medicine